AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapi...
– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hol...
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigatorsOngoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a bio
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on...
This is the newest page. Registered accounts read further back.